Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations

[1]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[2]  Yu-Chung Wu,et al.  EGFR mutations in non-small-cell lung cancer. , 2010, The Lancet. Oncology.

[3]  Ying Wang,et al.  A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. , 2009, American journal of human genetics.

[4]  M. Spitz,et al.  Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. , 2009, Cancer research.

[5]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[6]  Wen Tan,et al.  Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. , 2009, Cancer research.

[7]  Christopher I Amos,et al.  Common 5p15.33 and 6p21.33 variants influence lung cancer risk , 2008, Nature Genetics.

[8]  Simon Heath,et al.  Lung cancer susceptibility locus at 5p15.33 , 2008, Nature Genetics.

[9]  Tony Fletcher,et al.  Sequence variant on 8q24 confers susceptibility to urinary bladder cancer , 2008, Nature Genetics.

[10]  H. Tsukuma,et al.  Trends in Lung Cancer Incidence by Histological Type in Osaka, Japan , 2008, Japanese journal of clinical oncology.

[11]  Chih‐Hsin Yang.  EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. , 2008, Lung cancer.

[12]  G. Mills,et al.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 , 2008, Nature Genetics.

[13]  Daniel F. Gudbjartsson,et al.  A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.

[14]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[15]  Yusuke Nakamura,et al.  From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma , 2008, General thoracic and cardiovascular surgery.

[16]  P. Hainaut,et al.  Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. , 2008, Carcinogenesis.

[17]  N. Rothman,et al.  Family History of Cancer and Risk of Lung Cancer among Nonsmoking Chinese Women , 2007, Cancer Epidemiology Biomarkers & Prevention.

[18]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[19]  E. Flores.  The Roles of p63 in Cancer , 2007, Cell cycle.

[20]  C. Liam,et al.  Changes in the distribution of lung cancer cell types and patient demography in a developing multiracial Asian country: experience of a university teaching hospital. , 2006, Lung cancer.

[21]  Yusuke Nakamura,et al.  [BioBank Japan project]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[22]  F. Bray,et al.  International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising , 2005, International journal of cancer.

[23]  T. Eisen,et al.  Systematic review of the relationship between family history and lung cancer risk , 2005, British Journal of Cancer.

[24]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[25]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[27]  Shih-Feng Tsai,et al.  High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.

[28]  U. Moll,et al.  p63 and p73: roles in development and tumor formation. , 2004, Molecular cancer research : MCR.

[29]  J. Coebergh,et al.  The changing epidemiology of lung cancer in Europe. , 2003, Lung cancer.

[30]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Yusuke Nakamura,et al.  A high-throughput SNP typing system for genome-wide association studies , 2001, Journal of Human Genetics.

[32]  Y. Ikawa,et al.  p51A (TAp63γ), a p53 homolog, accumulates in response to DNA damage for cell regulation , 2000, Oncogene.

[33]  A. Oshima,et al.  Trends of Lung Cancer Incidence by Histologic Type: A Population‐based Study in Osaka, Japan , 1999, Japanese journal of cancer research : Gann.

[34]  L. Appel,et al.  Projected mortality from lung cancer in South Korea, 1980-2004. , 1998, International journal of epidemiology.

[35]  M. Thun,et al.  Cigarette smoking and changes in the histopathology of lung cancer. , 1997, Journal of the National Cancer Institute.